Evidence map›Paper›PMID 36792848›Full record

SynthesisClinical rheumatology2023

The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis.

Mohamed Abuelazm, Ahmed Ghanem, Abdelrahman Mahmoud, Aml M Brakat, Mohamad A Elzeftawy, Aya Mamdouh Fayoud, Ahmed K Awad, Basel Abdelazeem

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Mohamed Abuelazm *Faculty of Medicine, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0002-2514-0689
Ahmed Ghanem *Cardiology Department, The Lundquist Institute, Torrance, CA, USA.ORCID http://orcid.org/0000-0002-1547-7886
Abdelrahman MahmoudFaculty of Medicine, Minia University, Minia, Egypt.ORCID http://orcid.org/0000-0001-7514-1623
Aml M BrakatFaculty of Medicine, Zagazig University, Zagazig, Egypt.ORCID http://orcid.org/0000-0001-9786-2237
Mohamad A ElzeftawyFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0001-5619-9803
Aya Mamdouh FayoudFaculty of Pharmacy, Kafr El-Shiekh University, Kafr El-Shiekh, Egypt.ORCID http://orcid.org/0000-0003-4139-8812
Ahmed K AwadFaculty of Medicine, Ain-Shams University, Cairo, Egypt. ahmedkawad@gmail.com.ORCID http://orcid.org/0000-0001-6647-1866
Basel AbdelazeemDepartment of Internal Medicine, McLaren Health Care, Flint, MI, USA.ORCID http://orcid.org/0000-0002-2919-6196
Tanta University · EGAin Shams University · EGArish University · EGMcLaren Health Care · USMinia University · EGZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olokizumab (OKZ) is a novel IL-6 inhibitor that directly targets IL-6 rather than its receptor. We aim to evaluate the efficacy and safety of OKZ for patients with rheumatoid arthritis (RA) and to investigate the optimal treatment regimen. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, CENTRAL, SCOPUS, EMBASE, and PubMed until August 31, 2022. We used the risk ratio (RR) and mean difference (MD) for dichotomous and continuous outcomes, respectively, presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022358082. Five RCTs with 2277 patients were included. OKZ significantly improved the American College of Rheumatology criteria (ACR) 20 (RR: 1.97 with 95% CI [1.49, 2.58], P = 0.00001), ACR50 (RR: 3.83 with 95% CI [2.13, 6.87], P = 0.00001), ACR70 (RR: 3.83 with 95% CI [2.13, 6.87], P = 0.00001), disease activity score 28 based on C-reactive protein (DAS28-CRP) (RR: 3.91 with 95% CI [2.65, 5.79], P = 0.00001), clinical disease activity index (CDAI) (RR: 2.80 with 95% CI [1.43, 5.48], P = 0.003), and health assessment questionnaire disability index (HAQ-DI) (MD: - 0.28 with 95% CI [- 0.38, - 0.18], P = 0.00001) after 12 weeks, compared to placebo. However, OKZ was also associated with a higher incidence of any adverse events (AEs) (RR: 1.15 with 95% CI [1.06, 1.25], P = 0.0005) and AEs leading to drug discontinuation (RR: 1.86 with 95% CI [1.05, 3.29], P = 0.03). OKZ is effective and with acceptable safety profile when administrated with methotrexate in patients with RA not adequately controlled by tumor necrosis factor inhibitors; however, more large-scale RCTs are still required to investigate the optimal dosing, long-term effects, and comparative efficacy versus established biological DMARDs. Key Points • OKZ is effective especially with methotrexate in RA patients.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAntibodies, Monoclonal, HumanizedHumansMethotrexateTreatment OutcomeAntibodies, Monoclonal, HumanizedAntirheumatic AgentsMethotrexateolokizumabDMARDsMeta-analysisOKZOlokizumabRheumatoid arthritisSystematic review

Identifiers

PMID36792848
PMCPMC10202974
OpenAlexW4321003825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.